{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"description":"The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria.","groups":[{"description":"Investigators choice of Letrozole 2.5 mg po qd continuously, tamoxifen 20mg po bid continuously, paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d, 3 wks on, 1 wk off, Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d, Topotecan 4.0mg/m2 over 30 min on day 1,8 and 15 of a 28 day cycle. For each arm, 1 cycle - 28 days","id":"OG000","title":"Arm A - Control Arm"},{"description":"Trametinib 2 mg po daily continuous treatment, For each arm, 1 cycle = 28 days","id":"OG001","title":"Arm B - Experimental Arm"}],"paramType":"NUMBER","populationDescription":"Randomized patients","reportingStatus":"POSTED","timeFrame":"Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B","title":"Objective Tumor Response Rate (Complete Response and Partial Response)","type":"SECONDARY","unitOfMeasure":"participants"}